Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04564378 · ClinicalTrials.gov registry record
Association Between Fuchs' Endothelial Corneal Dystrophy Severity and Estrogen Exposure
A clinical trial, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- 43
- Enrollment target
NCT04564378: Completed study, sponsored by State University of New York at Buffalo.
NCT04564378 is a clinical trial that has completed, run by State University of New York at Buffalo. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04564378 has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
This study is being done to discover if there is a link between estrogen exposure and the severity of Fuchs Endothelial Corneal Disease. We are trying to understand if the decrease in estrogen levels in post-menopausal women may be a reason why FECD is seen more often in women than men.
Primary Outcome
Difference in measures of estriadiol exposure between individuals with mild vs. severe FECD
Interventions
- OTHER This is an observational study. There is no therapeutic intervention.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-01-17 |
| Est. Completion | 2023-09-01 |
What the finished NCT04564378 record still lists
NCT04564378 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which This is an observational study. There is no therapeutic intervention. is the first listed.
NCT04564378 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04564378 about?
NCT04564378 is a clinical study titled "Association Between Fuchs' Endothelial Corneal Dystrophy Severity and Estrogen Exposure". This study is being done to discover if there is a link between estrogen exposure and the severity of Fuchs Endothelial Corneal Disease. We are trying to understand if the decrease in estrogen levels in post-menopausal women may be a reason why FECD is seen more often in women than men.
What is the current status of trial NCT04564378?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2018-01-17. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT04564378?
The interventions under investigation include: This is an observational study. There is no therapeutic intervention. (OTHER).
Who is sponsoring clinical trial NCT04564378?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI